ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,487.03
0.25%
Dow Jones
38,834.86
0.15%
US Dollar vs MXN
18.4366
0.12%
Brent Oil
84.695
-0.11%
Bitcoin
64,889.34
-0.38%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Allakos Inc (ALLK)

  7. Allakos Inc (ALLK) Noticias

ALLK

Allakos (ALLK)

Allakos Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ALLK
FechaHoraFuenteTítuloSímboloCompañía
10/06/202416:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
07/06/202414:43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLKAllakos Inc
28/05/202406:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLKAllakos Inc
28/05/202406:02GlobeNewswire Inc.Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous UrticariaNASDAQ:ALLKAllakos Inc
09/05/202416:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLKAllakos Inc
09/05/202415:02GlobeNewswire Inc.Allakos Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:ALLKAllakos Inc
14/03/202415:02GlobeNewswire Inc.Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
26/02/202406:02GlobeNewswire Inc.Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024NASDAQ:ALLKAllakos Inc
16/02/202418:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
14/02/202415:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALLKAllakos Inc
12/02/202406:02GlobeNewswire Inc.Allakos Announces Publication Highlighting AK006 Mast Cell InhibitionNASDAQ:ALLKAllakos Inc
02/02/202411:31Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ALLKAllakos Inc
26/01/202415:20Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALLKAllakos Inc
16/01/202406:02GlobeNewswire Inc.Allakos Announces a Restructuring to Focus on Development of AK006NASDAQ:ALLKAllakos Inc
16/01/202406:00GlobeNewswire Inc.Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary EndpointsNASDAQ:ALLKAllakos Inc
05/01/202415:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALLKAllakos Inc
26/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALLKAllakos Inc
13/11/202316:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALLKAllakos Inc
13/11/202315:02GlobeNewswire Inc.Allakos Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
30/08/202315:05GlobeNewswire Inc.Allakos Appoints Neil Graham to its Board of DirectorsNASDAQ:ALLKAllakos Inc
09/08/202315:02GlobeNewswire Inc.Allakos Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
02/08/202315:05GlobeNewswire Inc.Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of DirectorsNASDAQ:ALLKAllakos Inc
12/06/202306:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALLKAllakos Inc
12/06/202306:02GlobeNewswire Inc.Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell InhibitionNASDAQ:ALLKAllakos Inc
05/06/202315:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALLKAllakos Inc
05/06/202306:02GlobeNewswire Inc.Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023NASDAQ:ALLKAllakos Inc
02/06/202315:51Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:ALLKAllakos Inc
09/05/202315:14Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALLKAllakos Inc
09/05/202315:02GlobeNewswire Inc.Allakos Provides Business Update and Reports First Quarter 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
20/04/202315:25Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ALLKAllakos Inc
 Showing the most relevant articles for your search:NASDAQ:ALLK

Su Consulta Reciente

TG
ACBB
Alpha Services
AMEX
EWT
iShares MSCI Taiwan ETF
BIT
P1PV40
BNP Paribas Issuance
BIT
P1T6R1
BNP Paribas Issuance
BIT
P15IL1
BNP Paribas Issuance
BIT
UC4AZY
Unicredit Bank
NASDAQ
DASH
DoorDash
TSXV
RAK
Rackla Metals
TG
PNL
Essential Metals
BOV
BBASR54
BBASR54 Ex:26,14
COIN
EROWANUST
erowan
BIT
P1MM36
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados